Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer

Le Chevalier, T., Arriagada, R., Le Pechoux, C., Grunenwald, D., Dunant, A., Pignon, J. P., Tarayre, M., Abratt, R., Arriagada, R., Bergman, B., Gralla, R., Grunenwald, D., Le Chevalier, T., Orlowski, T., Papadakis, E., Pinel, M. I. Sathler, Araujo, C., Della Torre, H., de Solchaga, M. Masetto, Abdi, E., Blum, R., Ball, D., Basser, R., De Boer, R., Bishop, J., Brigham, B., Davis, S., Fox, D., Richardson, G., Wyld, D., Pirker, R., Humblet, Y., Delaunois, L., Van Meerbeeck, J. P., Germonpre, P., Vansteenkiste, J., Nackaerts, K., Pinel, M. I. S., Vauthier, G., Younes, R. N., Arriagada, R., Baeza, R., Carvajal, P., Kleinman, S., Orlandi, L., Castro, C., Godoy, J., Kosatova, K., Gaafar, R., Azarian, R., Benichou, M., Boudoux, L., Boyer, G., Chirat, E., Chomy, F., Coetmeur, D., Couderc, L. J., Coudert, B., Crequit, J., David, P., Delaval, P., Dohollou, N., Foucher, P., Gonzalez, G., Jeanfaivre, T., Joveniaux, A., Kanoui, A. A., Le Chevalier, T., Le Pechoux, C., Baldeyrou, P., Debrosse, D., Girard, P., Grunenwald, D., Ruffie, P., Leclerc, P., Milleron, B., Monnet, I., Monnot, H., Morere, J. F., Naman, H., Dides, S., Noel, J. P., Otto, J., Ozanne, F., Ozenne, G., Parent, F., Peureux, M., Picon, B., Pujol, J. L., Quoix, E., Rabut, H., Riviere, A., Gervais, R., Icard, P., Rixe, O., Deplanque, G., Sevin, D., Spaeth, D., Tourani, J. M., Toussaint, C., Tuchais, C., Vannetzel, J. M., VArflet, F., Virally, J., Zaegel, M., Zalcman, G., Livatorwski, A., Eberhardt, W., Alexopoulos, C., Apostolopoulou, F., Bachlitzanakis, N., Bellenis, I., Christaki, P., Dosios, T., Georgoulias, V., Iliadis, K., Kardamakis, D., Konstantinou, M, Kotsovoulou, V., Pouliou, M., Michalopoulou, P., Papadakis, E., Agelidou, A., Zarogoulidis, K., Gottfried, M., Kovner, F., Agostara, B., Ascoli, M, Brigandi, A., Cigolari, S., Colucci, G., De Braud, F., Dirosa, T., Giglio, A., Maiorino, A., Masotti, A., Rusca, M., Ogawara, M., Osada, H., Park, K., Jackevicius, A., Smickoska, S., El Gueddari, B. El Khalil, Aaesebo, U., Desales, R., Furman, M., Kozlowski, M., Laudanski, J., Grodzki, T., Orlowski, T., Chabowski, M., Pluzanska, A., Gaspar, L., Ciuleanu, T., Baumohl, J., Cerna, M., Bitenc, M., Abratt, R., Chasen, M., Alberola, V., Azagra, P., Garcia, P. Ballesteros, Cardenal, F., Curto, C. Pallares, Salinas, J., Serrate, R. Surbirana, Bergman, B., Andersson, L., Hero, U., Mansson, T., Martinsson, J. E., Hillerdal, G., Agrenius, V., Sederholm, C., Arvidsson, I., Ydreborg, S. O., Thaning, L., Sjoegren, A., Jonsson, P., Grip, H., Singer, J., Lundgren, R., Brodin, O., Andejani, D., Branden, E., Lamberg, K., Riska, H., Egli, F., Joss, R,, Martinelli, G,, Roth, A,, Stahel, R,, Stupp, R,, El Kamel, A,, Gralla, R,, Cole, J. T., Jahanzeb, M., Wiznitzer, I., Masters, G. A., Radosavljevic, G., Babiker, A., Green, M., Osterlind, K., Taube, A. and Wedel, H. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 350 4: 351-360. doi:10.1056/NEJMoa031644

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ371961_OA.pdf application/pdf 126.61KB 0

Author Le Chevalier, T.
Arriagada, R.
Le Pechoux, C.
Grunenwald, D.
Dunant, A.
Pignon, J. P.
Tarayre, M.
Abratt, R.
Arriagada, R.
Bergman, B.
Gralla, R.
Grunenwald, D.
Le Chevalier, T.
Orlowski, T.
Papadakis, E.
Pinel, M. I. Sathler
Araujo, C.
Della Torre, H.
de Solchaga, M. Masetto
Abdi, E.
Blum, R.
Ball, D.
Basser, R.
De Boer, R.
Bishop, J.
Brigham, B.
Davis, S.
Fox, D.
Richardson, G.
Wyld, D.
Pirker, R.
Humblet, Y.
Delaunois, L.
Van Meerbeeck, J. P.
Germonpre, P.
Vansteenkiste, J.
Nackaerts, K.
Pinel, M. I. S.
Vauthier, G.
Younes, R. N.
Arriagada, R.
Baeza, R.
Carvajal, P.
Kleinman, S.
Orlandi, L.
Castro, C.
Godoy, J.
Kosatova, K.
Gaafar, R.
Azarian, R.
Benichou, M.
Boudoux, L.
Boyer, G.
Chirat, E.
Chomy, F.
Coetmeur, D.
Couderc, L. J.
Coudert, B.
Crequit, J.
David, P.
Delaval, P.
Dohollou, N.
Foucher, P.
Gonzalez, G.
Jeanfaivre, T.
Joveniaux, A.
Kanoui, A. A.
Le Chevalier, T.
Le Pechoux, C.
Baldeyrou, P.
Debrosse, D.
Girard, P.
Grunenwald, D.
Ruffie, P.
Leclerc, P.
Milleron, B.
Monnet, I.
Monnot, H.
Morere, J. F.
Naman, H.
Dides, S.
Noel, J. P.
Otto, J.
Ozanne, F.
Ozenne, G.
Parent, F.
Peureux, M.
Picon, B.
Pujol, J. L.
Quoix, E.
Rabut, H.
Riviere, A.
Gervais, R.
Icard, P.
Rixe, O.
Deplanque, G.
Sevin, D.
Spaeth, D.
Tourani, J. M.
Toussaint, C.
Tuchais, C.
Vannetzel, J. M.
VArflet, F.
Virally, J.
Zaegel, M.
Zalcman, G.
Livatorwski, A.
Eberhardt, W.
Alexopoulos, C.
Apostolopoulou, F.
Bachlitzanakis, N.
Bellenis, I.
Christaki, P.
Dosios, T.
Georgoulias, V.
Iliadis, K.
Kardamakis, D.
Konstantinou, M
Kotsovoulou, V.
Pouliou, M.
Michalopoulou, P.
Papadakis, E.
Agelidou, A.
Zarogoulidis, K.
Gottfried, M.
Kovner, F.
Agostara, B.
Ascoli, M
Brigandi, A.
Cigolari, S.
Colucci, G.
De Braud, F.
Dirosa, T.
Giglio, A.
Maiorino, A.
Masotti, A.
Rusca, M.
Ogawara, M.
Osada, H.
Park, K.
Jackevicius, A.
Smickoska, S.
El Gueddari, B. El Khalil
Aaesebo, U.
Desales, R.
Furman, M.
Kozlowski, M.
Laudanski, J.
Grodzki, T.
Orlowski, T.
Chabowski, M.
Pluzanska, A.
Gaspar, L.
Ciuleanu, T.
Baumohl, J.
Cerna, M.
Bitenc, M.
Abratt, R.
Chasen, M.
Alberola, V.
Azagra, P.
Garcia, P. Ballesteros
Cardenal, F.
Curto, C. Pallares
Salinas, J.
Serrate, R. Surbirana
Bergman, B.
Andersson, L.
Hero, U.
Mansson, T.
Martinsson, J. E.
Hillerdal, G.
Agrenius, V.
Sederholm, C.
Arvidsson, I.
Ydreborg, S. O.
Thaning, L.
Sjoegren, A.
Jonsson, P.
Grip, H.
Singer, J.
Lundgren, R.
Brodin, O.
Andejani, D.
Branden, E.
Lamberg, K.
Riska, H.
Egli, F.
Joss, R,
Martinelli, G,
Roth, A,
Stahel, R,
Stupp, R,
El Kamel, A,
Gralla, R,
Cole, J. T.
Jahanzeb, M.
Wiznitzer, I.
Masters, G. A.
Radosavljevic, G.
Babiker, A.
Green, M.
Osterlind, K.
Taube, A.
Wedel, H.
Title Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
Journal name New England Journal of Medicine   Check publisher's open access policy
ISSN 0028-4793
1533-4406
Publication date 2004-01-22
Year available 2011
Sub-type Article (original research)
DOI 10.1056/NEJMoa031644
Open Access Status File (Publisher version)
Volume 350
Issue 4
Start page 351
End page 360
Total pages 10
Place of publication Waltham, MA, United States
Publisher Massachusetts Medical Society
Language eng
Abstract BACKGROUND:
Formatted abstract
Background: On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer.

Methods: We randomly assigned patients either to three or four cycles of cisplatin-based chemotherapy or to observation. Before randomization, each center determined the pathological stages to include, its policy for chemotherapy (the dose of cisplatin and the drug to be combined with cisplatin), and its postoperative radiotherapy policy. The main end point was overall survival.

Results: A total of 1867 patients underwent randomization; 36. 5 percent had pathological stage I disease, 24.2 percent stage II, and 39.3 percent stage III. The drug allocated with cisplatin was etoposide in 56.5 percent of patients, vinorelbine in 26.8 percent, vinblastine in 11.0 percent, and vindesine in 5.8 percent. Of the 932 patients assigned to chemotherapy, 73. 8 percent received at least 240 mg of cisplatin per square meter of body-surface area. The median duration of follow-up was 56 months. Patients assigned to chemotherapy had a significantly higher survival rate than those assigned to observation (44.5 percent vs. 40.4 percent at five years [469 deaths vs. 504]; hazard ratio for death, 0.86; 95 percent confidence interval, 0.76 to 0.98; P<0.03). Patients assigned to chemotherapy also had a significantly higher disease-free survival rate than those assigned to observation (39.4 percent vs. 34.3 percent at five years [518 events vs. 577]; hazard ratio, 0.83; 95 percent confidence interval, 0.74 to 0.94; P< 0.003). There were no significant interactions with prespecified factors. Seven patients (0.8 percent) died of chemotherapy-induced toxic effects.

Conclusions: Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer.
Keyword Oncology
Respiratory System
Oncology
Respiratory System
ONCOLOGY
RESPIRATORY SYSTEM
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1350 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1687 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 24 Oct 2015, 05:30:21 EST by System User on behalf of Learning and Research Services (UQ Library)